Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents. by Mizuhara, Tsukasa et al.
Title
Structure-activity relationship study of pyrimido[1,2-
c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV
agents.
Author(s)Mizuhara, Tsukasa; Oishi, Shinya; Ohno, Hiroaki; Shimura,Kazuya; Matsuoka, Masao; Fujii, Nobutaka
CitationBioorganic & medicinal chemistry (2012), 20(21): 6434-6441
Issue Date2012-11-01
URL http://hdl.handle.net/2433/161054




Structure–activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives 

















Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan 
b











Shinya Oishi, Ph.D. and Nobutaka Fujii, Ph.D. 
Graduate School of Pharmaceutical Sciences 
Kyoto University 
Sakyo-ku, Kyoto, 606-8501, Japan 
Tel: +81-75-753-4551; Fax: +81-75-753-4570,  




3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) is an antiretroviral 
agent with submicromolar inhibitory activity against human immunodeficiency virus-1 (HIV-1) and 
HIV-2 infection. In the current study, the structure–activity relationships of accessory groups at the 
3- and 9-positions of pyrimido[1,2-c][1,3]benzothiazin-6-imine were investigated for the 
development of more potent anti-HIV agents. Several different derivatives containing a 9-aryl group 
were designed and synthesized using Suzuki-Miyaura cross-coupling and Ullmann coupling 
reactions. Modification of the m-methoxyphenyl or benzo[d][1,3]dioxol-5-yl group resulted in 
improved anti-HIV activity. In addition, the 2,4-diazaspiro[5.5]undec-2-ene-fused 
benzo[e][1,3]thiazine derivatives were designed and tested for their anti-HIV activities. The most 
potent 9-(benzo[d][1,3]dioxol-5-yl) derivative was 2–3-fold more effective against several strains of 
HIV-1 and HIV-2 than the parent compound, PD 404182. 
 
Keywords: Anti-HIV agents, PD 404182, Pyrimidobenzothiazine 
 
Abbreviations: CCR5, CC chemokine receptor type 5; CXCR4, CXC chemokine receptor type 4; 
MAGI, Multinuclear activation of a galactosidase indicator; NNRTI, Non-nucleoside reverse 
transcriptase inhibitors; NRTI, Nucleoside reverse transcriptase inhibitors 
1. Introduction  
Highly active antiretroviral therapy, involving the co-administration of nucleoside reverse 
transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and/or 
protease inhibitors, is a standard treatment regimen for human immunodeficiency virus (HIV) 
infections. This regimen suppresses the replication of HIV and controls disease progression in 
HIV-infected patients.
1,2
 Unfortunately, however, an increasing number of patients with HIV 
infection/AIDS have failed to respond to the current antiretroviral therapeutics because of serious 
problems including the emergence of drug-resistant HIV variants
3
 and drug-related adverse effects.
4
 
With this in mind, there is therefore a continuous need to develop novel anti-HIV drugs that are 
more effective against drug-resistant viruses and produce fewer adverse effects. Recently, a series 
of extensive studies led to the development of a series of novel antiretrovirals with new mechanisms 
of action for anti-HIV therapy, including a fusion inhibitor (enfuvirtide),
5-7
 an integrase inhibitor 
(raltegravir),
8,9
 and a CC chemokine receptor type 5 (CCR5) antagonist (maraviroc).
10,11
 CXC 









 represent promising alternative anti-HIV agents. 
3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) (1) was previously 
reported as an antimicrobial agent that inhibited 3-deoxy-D-manno-octulosonic acid 8-phosphate 
synthase
27
 and phosphopantetheinyl transferase (Figure 1).
28,29
 Following a recent random screening 
program using a multinuclear activation of a galactosidase indicator (MAGI) assay, compound 1 
was identified as a new antiretroviral candidate with a high therapeutic index (CC50/EC50 > 200). 
The MAGI assay allows for the inhibitory activity of an early-stage HIV infection, including 
inhibition of the virus attachment and membrane fusion to host cells, to be effectively evaluated.
30
 
Compound 1 showed a similar antiviral profile in HIV-1 infection to DS 5000
31
 (adsorption 
inhibitor) and enfuvirtide (fusion inhibitor). The virucidal effects of compound 1 against the human 
hepatitis C virus, HIV, and simian immunodeficiency virus have also been reported.
32,33
 The 
mechanism of action for compound 1, however, has not yet been fully understood. 
In our previous structure–activity relationship (SAR) study of compound 1,34 a number of PD 
404182 derivatives were designed and synthesized according to a series of facile synthetic 
procedures,
35,36
 in which the tricyclic heterocycles related to PD 404182 were easily obtained in a 
few steps from benzaldehydes via C–H functionalization or aromatic nucleophilic substitution. The 
6-6-6 fused pyrimido[1,2-c][1,3]benzothiazine scaffold and the heteroatom arrangement in the 
1,3-thiazin-2-imine moiety are indispensable for the inhibitory activity of compound 1 against HIV 
infection (Figure 1). Optimization studies indicated that the introduction of a hydrophobic group on 
the benzene ring and the cyclic amidine substructures effectively improved the antiviral activity by 
generating a potentially favorable interaction(s) with the target molecule(s). The most potent 
compounds identified were 2-fold more potent than PD 404182 and contained a phenyl group at 
9-position of pyrimido[1,2-c][1,3]benzothiazine (compound 2) or a geminal dimethyl group on the 
pyrimidine moiety (compound 3) (Figure 2). 
In the current study, further structural optimization was conducted from the lead compounds 2 
and 3 according to three approaches (Figure 2), including the introduction of substituents on the 
9-phenyl group (I), the substitution of the 9-phenyl group with fused arenes or heterocycles (II), and 
the modification of the cyclic amidine moiety (III). The anti-HIV profiles of the most potent 
derivative are also described. 
 
2. Results and discussion 
2.1. Synthesis of 9-aryl-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine 
derivatives. 
The 9-Aryl-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives (7 and 8) 
were synthesized using a Suzuki-Miyaura cross-coupling reaction
37-39
 of N-(tert-butyl)-protected 
bromide 4 with aryl boronic acid (pinacol ester) or by an Ullmann coupling
40
 with pyrazole or 
imidazole (Scheme 1). Subsequent trifluoroacetic acid (TFA)-mediated deprotection of the 
tert-butyl groups afforded the desired biaryl-type derivatives. 
 
2.2. Synthesis of spiropyrimidine-fused benzothiazinimine derivatives. 
The synthesis of the spiropyrimidine-fused derivatives started with the dialkylation of 
malononitrile with dihaloalkanes (9, 10, or 12, Scheme 2). BH3-mediated reduction of the alkylated 
malononitriles (13–15) followed by oxidative amidination41 with 4-bromo-2-fluorobenzaldehyde 
gave the 2-phenyl-1,4,5,6-tetrahydropyrimidine derivatives (16–18). Subsequent exposure of 
compounds 16–18 to tert-butylisothiocyanate provided the tetracyclic compounds 19, 21, and 23a. 
Deprotection of the tert-butyl groups in compounds 19, 21, and 23a afforded the desired 
spiropyrimidine-fused benzothiazinimine derivatives (20, 22, and 24a). The substitution of the 
p-methoxybenzyl (PMB) group in compound 24a was also attempted (Scheme 3). The treatment of 
compound 23a with methyl chloroformate or acetyl chloride directly provided derivatives 23b and 
23c, respectively. A two-step procedure, including the removal of the PMB group by treatment with 
1-chloroethyl chloroformate followed by modification with mesyl chloride (MsCl) or trimethylsilyl 
isocyanate (TMSNCO) was used for the synthesis of the derivatives 23d and 23e, respectively, 
because the reaction of compound 23a with MsCl and TMSNCO failed. Deprotection of the 
tert-butyl group in 23b–e afforded the respective N-substituted derivatives 24b–e. 
 
2.3. Structure–activity relationships of 9-phenylpyrimido[1,2-c][1,3]benzothiazine 
derivatives. 
We initially examined substituent effects at the para-position of the 9-phenyl group of compound 
2 (Table 1). The introduction of methoxycarbonyl (7a), cyano (7b), nitro (7c), and trifluoromethyl 
(7d) groups slightly reduced the anti-HIV activity (EC50 = 0.44–0.81 M), whereas a significant 
decrease in the anti-HIV activity was observed following the introduction of a carbamoyl group (7e) 
with hydrogen-bond donor/acceptor properties (EC50 = 8.71 M). Compounds containing a 
hydrophobic group, including methoxy (7f, EC50 = 0.24 M), methylthio (7g, EC50 = 0.20 M), and 
trifluoromethoxy (7h, EC50 = 0.38 M) groups showed similar levels of anti-HIV activity to that of 
compound 2. These results indicated that the hydrophobic and electron donating properties of these 
substituents had positive impacts on improving the anti-HIV activity. 
Similar SARs were observed following modifications at the meta-position of the 9-phenyl group 
(Table 1). For example, the addition of the electron-withdrawing methoxycarbonyl (7i), cyano (7j), 
and nitro (7k) groups resulted in a slight decrease in the anti-HIV activity (EC50 = 0.39–1.26 M), 
whereas the hydrophilic (1-hydroxy)ethyl (7l, EC50 = 1.19 M), acetamido (7m, EC50 >10 M), 
mesylamido (7n, EC50 >10 M), and hydroxy (7o, EC50 = 2.62 M) groups led to a reduction or 
loss in the levels of anti-HIV activity. In contrast, the introduction of a methoxy group (7p) at the 
meta-position of the 9-phenyl group improved the inhibitory activity (EC50 = 0.15 M). The more 
hydrophobic isopropoxy group (7q) maintained the anti-HIV activity of compound 2 (EC50 = 0.32 
M), whereas the introduction of a phenyl group (7r) led to a decrease in the inhibitory activity 
(EC50 = 1.35 M). 
Similar anti-HIV activities to that of compound 2 were also exhibited by the ortho-methoxy (7s) 
and ortho-phenyl (7t) derivatives (EC50 = 0.41 and 0.32 M, respectively), suggesting that the 
twisted conformation of the biaryl axis in the 9-aryl-modified PD 404182 derivatives can be 
tolerated and can interact with the target molecule(s). 
To develop more potent anti-HIV agents, several compounds were designed with bis- and 
tris-modifications on the 9-phenyl group of compound 2 (Table 1). The introduction of the 
3,4-dimethoxy (7u, EC50 = 0.27 M) and 3,4,5-trimethoxy (7v, EC50 = 0.25 M) groups did not 
alter the bioactivity. The Cl-modified derivatives 7w and 7x exhibited similar levels of potency to 
compound 2 (EC50 = 0.32 and 0.48 M, respectively). Taken together, these results suggest that the 
hydrophobic property of the phenyl substituting group may provide the predominant contribution in 
any potential interaction with the target molecule(s). 
We proceeded to investigate the impact of introducing a bicyclic aromatic group at the 9-position 
of the pyrimido[1,2-c][1,3]benzothiazine scaffold (Table 2). Modifications with a variety of 
3,4-fused phenyl groups were investigated because the 2-naphthyl-modified analog (8a) exhibited 
slightly more potent anti-HIV activity (EC50 = 0.20 M) than that of the 1-naphthyl congener (8b, 
EC50 = 0.39 M). Compound 8c, which contained a benzo[d][1,3]dioxol-5-yl group, displayed 
inhibitory activity 2-fold greater than that of compound 2 (EC50 = 0.15 M), whereas the 
2,3-dihydrobenzo[b][1,4]dioxin-6-yl derivative 8d and quinolin-6-yl derivative 8e exhibited less 
favorable effects (EC50 = 0.26 and 0.25 M, respectively). The introduction of 
trifluoroacetylindolyl groups (8f and 8g) resulted in no anti-HIV activity, and the compounds also 
showed unexpected levels of cytotoxicity. 
The substitution of the 9-phenyl group with a variety of different heterocyclic substructures was 
also investigated (Table 2). Pyridine substitution (8h and 8i) led to a slight reduction in the 
anti-HIV activity (EC50 = 0.45 and 0.54 M, respectively), whereas the introduction of a furan (8j), 
benzofuran (8k), thiophene (8l), benzothiophene (8m), and pyrazole (8n) was well tolerated and 
had little impact on the activity relative to compound 2 (EC50 = 0.20–0.42 M). It is worthy of note 
that the substitution of the 9-phenyl group with a basic imidazole moiety led to a significant 
reduction in the anti-HIV (8o, EC50 = 5.12 M). 
Taken together, these data led to the identification of two highly potent compounds 7p and 8c 
(EC50 = 0.15 M), which contained m-methoxyphenyl and benzo[d][1,3]dioxol-5-yl groups, 
respectively. Furthermore, no cytotoxic effects were observed for these derivatives at 10 M in the 
MAGI assay. 
 
2.4. Structure–activity relationships of spiropyrimidine-fused benzothiazinimine 
derivatives. 
Several spiropyrimidine-fused derivatives were designed for the SAR study based on the geminal 
dimethylpyrimidine substructure 3 (Table 3)
42
. Cyclohexane (20) and N-methoxycarbonylpiperidine 
(24b) derivatives exhibited the similar levels of anti-HIV activity to that of the parent dimethyl 
derivative 3. In contrast, the tetrahydropyran (22) and N-(p-methoxybenzyl)piperidine (24a) 
derivatives exerted inhibitory activities that were 5–7-fold lower than that of the parent dimethyl 
derivative 3. The N-acetyl- (24c), N-methanesulfonyl- (24d), and N-carbamoyl- (24e) piperidine 
derivatives also provided reduced levels of antiviral activity. With this in mind, the 
N-alkoxycarbonyl piperidine group was identified as a linkage for the introduction of additional 
functional group(s) to PD 404182 with potent anti-HIV activity (24b). 
 
2.5. Anti-HIV profiles of the most potent derivative 8c. 
A time-of-drug addition study was carried out to further investigate the anti-HIV profile of the 
most potent derivative 8c as an anti-HIV agent (Figure 3). This assay has been used previously to 
approximately determine which stage in the replication cycle of HIV-1 is inhibited by the 
compound. Two compounds (1 and 8c) were selected for testing in this assay together with five 
standard anti-HIV agents, including DS5000 (adsorption inhibitor),
31







 and raltegravir (integrase inhibitor).
8,9
 The 
results revealed that the infection profile in the presence of compound 8c was similar to that of 
DS5000 and enfuvirtide, suggesting that 8c exerted its anti-HIV activity at the early stages of the 
viral infection, including the binding and fusion stage. This was similar to PD 404182, indicating 
that the bioactivity profile was not influenced by the newly appended functional group(s). 
We also evaluated the antiviral activity of compounds 1 and 8c against several HIV strains such 
as HIV-1NL4-3, HIV-1BaL, HIV-2EHO, and HIV-2ROD. This study enabled us to estimate the impact of 
the target molecules on the process of binding and fusion because these viruses have different 
susceptibilities
46
 to different anti-HIV agents. These results implied that compounds 1 and 8c 
exhibited their anti-HIV activity through different mechanisms from those of the known binding 
and fusion inhibitors including CCR5 antagonists, CXCR4 antagonists, and enfuvirtide. In addition, 




In conclusion, we have designed and synthesized a series of PD 404182 derivatives for the 
development of novel anti-HIV agents. The structural optimization study on the 9-position of 
pyrimido[1,2-c][1,3]benzothiazinimine identified two potent derivatives containing 
m-methoxyphenyl (7p) and benzo[d][1,3]dioxol-5-yl groups (8c) that exhibited threefold higher 
anti-HIV activity than that of PD 404182 (1). The common hydrophobic biaryl moiety is effective 
to improve the antiviral activity, providing potential interaction with the target molecule(s). In 
addition, we demonstrated that the most effective derivative, 8c, inhibited viral infection against all 
of the HIV strains examined and acted at the early stage of the HIV infection. The design and 







H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer. 
Chemical shifts are reported in δ (ppm) relative to Me4Si (CDCl3) or DMSO (DMSO-d6) as internal 
standards. 
13
C NMR spectra were referenced to the residual solvent signal. Exact mass (HRMS) 
spectra were recorded on a JMS-HX/HX 110A mass spectrometer. Melting points were measured 
by a hot stage melting point apparatus (uncorrected). For flash chromatography, Wakogel C-300E 
(Wako) or aluminium oxide 90 standardized (Merck) were employed. For preparative TLC, TLC 
silica gel 60 F254 (Merck) or TLC aluminium oxide 60 F254 basic (Merck) were employed. For 
analytical HPLC, a Cosmosil 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque, Inc., Kyoto, 
Japan) was employed with method A [a linear gradient of CH3CN containing 0.1% (v/v) TFA] or 
method B [a linear gradient of CH3CN containing 0.1% (v/v) NH3] at a flow rate of 1 mL/min on a 
Shimadzu LC-10ADvp (Shimadzu Corp., Ltd., Kyoto, Japan), and eluting products were detected 
by UV at 254 nm. The purity of the compounds was determined by combustion analysis or HPLC 
analysis as >95%.  
 
4.1.2. General procedure of Suzuki-Miyaura cross coupling for 9-aryl pyrimido[1,2-c][1,3]- 
thiazine derivatives 5 and 6: N-(tert-butyl)-3,4-dihydro-9-(4-methoxycarbonylphenyl)-2H,6H- 
pyrimido[1,2-c][1,3]benzothiazin-6-imine 5a. 
To a solution of bromide 4 (52.8 mg, 0.15 mmol) and 4-(methoxycarbonyl)phenylboronic acid 
(32.4 mg, 0.18 mmol) in a mixture of toluene (1.5 mL), EtOH (0.9 mL) and 1 M aq. K2CO3 (1.5 
mL) was added Pd(PPh3)4 (6.9 mg, 4 mol%) and PdCl2(dppf)·CH2Cl2 (3.7 mg, 3 mol%). After 
being stirred under reflux for 1 h, the mixture was extracted with CHCl3. The organic layers were 
dried over MgSO4 and concentrated. The residue was purified by flash chromatography over 
aluminum oxide with n-hexane–EtOAc (10:0 to 9:1) to give the compound 5a as colorless solid 
(47.3 mg, 77%): mp 201–202 °C (from CHCl3–n-hexane); IR (neat) cm
-1
: 1719 (C=O), 1593 
(C=N); 
1
H-NMR (400 MHz, CDCl3) δ: 1.40 (s, 9H, 3×CH3), 1.90-1.96 (m, 2H, CH2), 3.65 (t, J = 
5.5 Hz, 2H, CH2), 3.89 (t, J = 6.1 Hz, 2H, CH2), 3.94 (s, 3H, CH3), 7.36 (d, J = 1.7 Hz, 1H, Ar), 
7.44 (dd, J = 8.5, 1.7 Hz, 1H, Ar), 7.65 (d, J = 8.2 Hz, 2H, Ar), 8.10 (d, J = 8.2 Hz, 2H, Ar), 8.28 (d, 
J = 8.5 Hz, 1H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 21.9, 30.0 (3C), 45.2, 45.4, 52.1, 54.2, 123.0, 
124.8, 127.0 (2C), 127.3, 129.1, 129.6, 129.8, 130.2 (2C), 138.0, 141.7, 143.8, 147.5, 166.8; HRMS 
(FAB): m/z calcd for C23H26N3O2S [M + H]
+




To a solution of 4 (52.8 mg, 0.15 mmol), pyrazole (12.3 mg, 0.18 mmol), CuCl (1.5 mg, 0.015 
mmol) and K2CO3 (21.8 mg, 0.16 mol) in N-methylpyrrolidone (0.3 mL) was added acetylacetone 
(3.8 L, 0.038 mmol) under an Ar atmosphere. After being stirred at 130 °C for 19 h, EtOAc and 
brine was added. The organic layers were washed with H2O, and dried over MgSO4. After 
concentration, the residue was purified by flash chromatography over aluminum oxide with 
n-hexane–EtOAc (7:3) to give the title compound 6n as colorless solid (39.8 mg, 71%): mp 
132–133 °C (from CHCl3–n-hexane); IR (neat) cm
-1
: 1597 (C=N); 
1
H-NMR (400 MHz, CDCl3) δ: 
1.39 (s, 9H, 3×CH3), 1.90-1.96 (m, 2H, CH2), 3.63 (t, J = 5.6 Hz, 2H, CH2), 3.88 (t, J = 6.2 Hz, 2H, 
CH2), 6.48 (dd, J = 2.7, 1.8 Hz, 1H, Ar), 7.47 (dd, J = 8.8, 2.2 Hz, 1H, Ar), 7.56 (d, J = 2.2 Hz, 1H, 
Ar), 7.73 (d, J = 1.8 Hz, 1H, Ar), 7.94 (d, J = 2.7 Hz, 1H, Ar), 8.28 (d, J = 8.8 Hz, 1H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 21.8, 30.0 (3C), 45.0, 45.4, 54.2, 108.2, 114.3, 115.9, 125.4, 126.7, 
129.9, 130.8, 137.7, 141.0, 141.7, 147.3; HRMS (FAB): m/z calcd for C18H22N5S [M + H]
+
 
340.1596; found: 340.1598.  
 
4.1.4. General procedure of tert-butyl deprotection for pyrimido[1,2-c][1,3]benzothiazin- 
6-imines (7, 8, 20, 22, and 24): 3,4-dihydro-9-(4-methoxycarbonylphenyl)-2H,6H-pyrimido- 
[1,2-c][1,3]benzothiazin-6-imine (7a). 
TFA (2.0 mL) was added to a mixture of N-(tert-butyl)-protected pyrimido[1,2-c][1,3]benzo- 
thiazin-6-imine 5a (38.4 mg, 0.094 mmol) in small amount of CHCl3 and MS4Å (300 mg, powder, 
activated by heating with Bunsen burner). After being stirred under reflux for 1 h, the mixture was 
concentrated. To a stirring mixture of the residue in CHCl3 was added dropwise Et3N at 0 °C to 
adjust pH to 8–9. The whole was extracted with EtOAc. The extract was washed with sat. NaHCO3, 
brine, and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography over aluminum oxide with n-hexane–EtOAc (9:1 to 1:1) to give the title compound 
7a as colorless solid (27.3 mg, 83%): mp 185–186 °C (from CHCl3–n-hexane); IR (neat) cm
-1
: 1719 
(C=O), 1619 (C=N), 1566 (C=N); 
1
H-NMR (500 MHz, CDCl3) δ: 1.97-2.02 (m, 2H, CH2), 3.71 (t, 
J = 5.7 Hz, 2H, CH2), 3.94 (s, 3H, CH3), 4.04 (t, J = 6.0 Hz, 2H, CH2), 7.27 (d, J = 1.7 Hz, 1H, Ar), 
7.46 (dd, J = 8.0, 1.7 Hz, 1H, Ar), 7.63 (d, J = 8.6 Hz, 2H, Ar), 8.10 (d, J = 8.6 Hz, 2H, Ar), 8.30 (d, 
J = 8.0 Hz, 1H, Ar). 
13
C-NMR (125 MHz, CDCl3) δ: 21.0, 43.8, 45.0, 52.2, 122.0, 125.1, 126.2, 
126.9 (2C), 129.5, 129.6, 129.7, 130.2 (2C), 142.1, 143.4, 146.2, 153.0, 166.7; HRMS (FAB): m/z 
calcd for C19H18N3O2S [M + H]
+
 352.1120; found: 352.1119.  
 
4.1.5. Bis(2-chloroethyl)-N-(4-methoxybenzyl)amine (12).  
To a suspension of bis(2-chloroethyl)amine hydrochloride 11 (8.92 g, 50.0 mmol) in CH2Cl2 (300 
mL) were added Et3N (2.89 mL, 100.0 mmol) and 4-methoxybenzoyl chloride (6.77 mL, 50.0 
mmol). After being stirred at rt for 2 h, the reaction mixture was washed with 1N HCl, sat. NaHCO3, 
brine, and dried over MgSO4. After concentration, the residue was dissolved in anhydrous Et2O 
(250 mL) and LiAlH4 (2.1 g, 55.0 mmol) was slowly added at 0 °C under an Ar atmosphere. After 
being stirred at rt overnight, the reaction mixture was quenched by addition of water, 2N NaOH, 
and water. The mixture was dried over MgSO4. After concentration, the residue was purified by 
flash chromatography over silica gel with n-hexane–EtOAc (19:1) to give the title compound 12 as 
colorless oil (9.88 g, 75%): 
1
H-NMR (400 MHz, CDCl3) δ: 2.90 (t, J = 7.1 Hz, 4H, 2×CH2), 3.48 (t, 
J = 7.1 Hz, 4H, 2×CH2), 3.67 (s, 2H, CH2), 3.80 (s, 3H, CH3), 6.86 (d, J = 8.5 Hz, 2H, Ar), 7.24 (d, 
J = 8.5 Hz, 2H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 42.0 (2C), 55.2, 56.2 (2C), 58.6, 113.8 (2C), 
129.7 (2C), 130.7, 158.9; LRMS (FAB): m/z [M + H]
+
 262.  
 
4.1.6. 1-(4-Methoxybenzyl)piperidine-4,4-dicarbonitrile (15).  
To a solution of malononitrile (2.49 g, 37.7 mmol) in DMF (94.3 mL) was added K2CO3 (5.73 
mg, 41.5 mmol). After being stirred at 65 °C for 2 h, a solution of chloride 12 (9.88 mg, 37.7 mmol) 
in DMF (37.7 mL) was added. After being stirred at same temperature for 5 h, EtOAc was added. 
The mixture was washed with 5% aq. NaHCO3, and dried over MgSO4. After concentration, the 
residue was purified by flash chromatography over silica gel with n-hexane–EtOAc (2:1) to give the 
title compound 15 as yellow oil (8.13 g, 85%): IR (neat) cm
-1
: 2248 (C≡N); 1H-NMR (400 MHz, 
CDCl3) δ: 2.22 (t, J = 5.4 Hz, 4H, 2×CH2), 2.61 (br s, 4H, 2×CH2), 3.48 (s, 2H, CH2), 3.80 (s, 3H, 
CH2), 6.86 (d, J = 8.5 Hz, 2H, Ar), 7.19 (d, J = 8.8 Hz, 2H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 
31.1, 34.1 (2C), 48.5 (2C), 55.2, 61.9, 113.8 (2C), 115.4 (2C), 129.2, 130.1 (2C), 159.0; HRMS 
(FAB): m/z calcd for C15H18N3O [M + H]
+




To a solution of nitrile 15 (4.05 g, 15.9 mmol) in THF (39.8 mL) was added BH3 in THF (79.5 
mL, 79.5 mmol, 1.0 M) at 0 °C under an Ar atmosphere. The mixture was warmed to rt. After being 
stirred at 65 °C for 5 h, the reaction mixture was cooled to 0 °C, and 1N HCl was added. After 
being stirred at rt for 1 h, the mixture was basified with 2N NaOH. The whole was extracted with 
CHCl3 and dried over MgSO4. After concentration, the residue was dissolved in t-BuOH (159.0 
mL) and 4-bromo-2-fluorobenzaldehyde (3.23 g, 15.9 mmol) was added. After being stirred at 
70 °C for 30 min, K2CO3 (6.59 g, 47.7 mmol) and I2 (5.05 g, 19.9 mmol) were added. After being 
stirred at same temperature for 3 h, the reaction mixture was quenched with sat. Na2SO3 until the 
iodine color almost disappeared. The reaction mixture was basified with 2N NaOH. The whole was 
extracted with CHCl3, and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography over aluminium oxide with EtOAc–MeOH (10:0/95:5) to give the title compound 





H-NMR (500 MHz, CDCl3) δ: 1.45 (t, J = 5.4 Hz, 4H, 2×CH2), 2.35 (t, J = 5.4 Hz, 
4H, 2×CH2), 3.16 (s, 4H, 2×CH2), 3.40 (s, 2H, CH2), 3.73 (s, 3H, CH3), 4.63 (s, 1H, NH), 6.78 (d, J 
= 8.6 Hz, 2H, Ar), 7.14-7.23 (m, 4H, Ar), 7.62 (t, J = 8.3 Hz, 1H, Ar). 
13
C-NMR (100 MHz, CDCl3) 
δ: 27.3, 32.8 (2C), 49.1 (2C), 51.4 (2C), 55.2, 62.7, 113.5 (2C), 119.4 (d, J = 27.3 Hz), 122.7 (d, J = 
12.4 Hz), 123.7 (d, J = 9.9 Hz), 127.8 (d, J = 3.3 Hz), 130.2, 130.3 (2C), 131.7 (d, J = 4.1 Hz), 
150.3 (d, J = 1.7 Hz), 158.6, 159.7 (d, J = 251.6 Hz); 
19
F-NMR (500 MHz, CDCl3) δ: –114.6. 
HRMS (FAB): m/z calcd for C22H26BrFN3O [M + H]
+
 446.1243; found: 446.1237. 
 
4.1.8. General procedure for t-BuNCS mediated cyclization: 9-bromo-N-(tert-butyl)-1'- 
(4-methoxybenzyl)-2H-spiro[benzo[e]pyrimido[1,2-c][1,3]thiazin-3,4'-piperidin]-6(4H)-imine 
(23a).  
To a mixture of fluoride 18 (2.0 g, 4.48 mmol) and NaH (358.4 mg, 8.96 mmol; 60% oil 
suspension) in DMF (14.8 mL) was added t-BuNCS (1.14 mL, 8.96 mmol) under an Ar atmosphere. 
After being stirred at rt overnight, the reaction mixture was warmed to 60 °C. After being stirred at 
this temperature for 1 h, EtOAc was added. The resulting solution was washed with sat. NaHCO3, 
brine, and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography over aluminum oxide with n-hexane–EtOAc (10:0 to 9:1) to give the title 
compound 23a as colorless solid (2.28 g, 94%): mp 89–91 °C (from CHCl3–n-hexane); IR (neat) 
cm
-1
: 1577 (C=N); 
1
H-NMR (500 MHz, CDCl3) δ: 1.37 (s, 9H, 3×CH3), 1.49-1.52 (m, 4H, 2×CH2), 
2.40-2.46 (m, 4H, 2×CH2), 3.41 (s, 2H, CH2), 3.47 (s, 2H, CH2), 3.75 (s, 2H, CH2), 3.80 (s, 3H, 
CH3), 6.85 (d, J = 8.6 Hz, 2H, Ar), 7.22 (d, J = 8.6 Hz, 2H, Ar), 7.28-7.31 (m, 2H, Ar), 8.03 (d, J = 
8.6 Hz, 1H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 29.7, 29.9 (3C), 32.6 (2C), 49.2 (2C), 51.6, 54.3, 
55.2, 55.5, 62.7, 113.6 (2C), 124.5, 126.3, 126.8, 129.2, 130.0, 130.1, 130.4 (2C), 130.9, 137.5, 
146.3, 158.7; HRMS (FAB): m/z calcd for C27H34BrN4OS [M + H]
+
 541.1637; found: 541.1633.  
 
4.1.9. 9-Bromo-N-(tert-butyl)-1'-(methoxycarbonyl)-2H-spiro[benzo[e]pyrimido[1,2-c][1,3]- 
thiazin-3,4'-piperidin]-6(4H)-imine (23b).  
To the solution of N-(4-methoxybenzyl)piperidine 23a (40.6 mg, 0.075 mmol) in CH2Cl2 (0.38 
mL) was added methyl chloroformate (86.4 L, 1.13 mmol) at 0 °C under an Ar atmosphere. After 
being stirred at same temperature for 30 min, the reaction mixture was concentrated. The residue 
was purified by flash chromatography over silica gel with n-hexane–EtOAc (1:1) to give compound 
23b as a colorless solid (29.2 mg, 81%): mp 157–158 °C (from n-hexane); IR (neat) cm-1: 1699 
(C=O), 1577 (C=N); 
1
H-NMR (400 MHz, CDCl3) δ: 1.37 (s, 9H, 3×CH3), 1.46 (t, J = 5.6 Hz, 4H, 
2×CH2), 3.44 (br s, 4H, 2×CH2), 3.56 (br s, 2H, CH2), 3.70 (s, 3H, CH3), 3.81 (s, 2H, CH2), 
7.29-7.33 (m, 2H, Ar), 8.05 (d, J = 8.5 Hz, 1H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 29.9 (3C), 30.1, 
32.2 (2C), 39.9 (2C), 50.8, 52.5, 54.3, 55.2, 124.7, 126.1, 126.8, 129.3, 130.0, 130.9, 137.7, 146.3, 
155.9; HRMS (FAB): m/z calcd for C21H28BrN4O2S [M + H]
+




To the solution of N-(4-methoxybenzyl)piperidine 23a (54.2 mg, 0.10 mmol) in CH2Cl2 (0.5 mL) 
were added Et3N (28.9 L, 0.20 mmol) and 1-chloroethyl chloroformate (21.8 L, 0.20 mmol) at 
0 °C under an Ar atmosphere. After being stirred at same temperature for 30 min, the reaction 
mixture was concentrated. The residue was dissolved in MeOH (2.0 mL). After being stirred under 
reflux for 10 min, the reaction mixture was concentrated. The residue was dissolved in CHCl3, and 
was washed with sat. NaHCO3, brine, and dried over MgSO4. After concentration, the residue was 
dissolved in CH2Cl2 (1.0 mL) and Et3N (28.9 L, 0.20 mmol) and methanesulfonyl chloride (15.5 
L, 0.20 mmol) was added at rt under an Ar atmosphere. After being stirred at rt for 10 min, the 
reaction mixture was washed with sat. NaHCO3, brine, and dried over MgSO4. After concentration, 
the residue was purified by flash chromatography over aluminum oxide with n-hexane–EtOAc (6:4) 
to give compound 23d as a colorless solid (40.9 mg, 82%): mp 177 °C (from CHCl3–n-hexane); IR 
(neat) cm
-1
: 1577 (C=N), 1331 (NSO2), 1155 (NSO2); 
1
H-NMR (400 MHz, CDCl3) δ: 1.38 (s, 9H, 
3×CH3), 1.62 (t, J = 5.5 Hz, 4H, 2×CH2), 2.80 (s, 3H, CH3), 3.21-3.27 (m, 2H, CH2), 3.31-3.37 (m, 
2H, CH2), 3.46 (s, 2H, CH2), 3.84 (s, 2H, CH2), 7.29-7.33 (m, 2H, Ar), 8.05 (d, J = 8.5 Hz, 1H, Ar). 
13
C-NMR (100 MHz, CDCl3) δ: 29.8, 29.9 (3C), 32.0 (2C), 34.7, 42.0 (2C), 50.1, 54.4, 55.1, 124.8, 
125.9, 126.9, 129.4, 130.0, 130.8, 137.9, 146.3; HRMS (FAB): m/z calcd for C20H28BrN4O2S2 [M + 
H]
+
 499.0837; found: 499.0840. 
 
4.2. Determination of anti-HIV activity. 
The sensitivity of three HIV-1 strains and two HIV-2 strains was determined by the MAGI assay. 
The target cells (HeLa-CD4/CCR5-LTR/β-gal; 104 cells/well) were plated in 96-well flat microtiter 
culture plates. On the following day, the cells were inoculated with the HIV-1 (60 MAGI U/well, 
giving 60 blue cells after 48 h of incubation) and cultured in the presence of various concentrations 
of the test compounds in fresh medium. Forty-eight hours after viral exposure, all the blue cells 
stained with X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) were counted in each well. 
The activity of test compounds was determined as the concentration that blocked HIV-1 infection 
by 50% (50% effective concentration [EC50]). EC50 was determined by using the following formula:  
EC50 = 10^[log(A/B)×(50 – C)/(D – C) + log(B)], 
wherein 
A: of the two points on the graph which bracket 50% inhibition, the higher concentration of the test 
compound,  
B: of the two points on the graph which bracket 50% inhibition, the lower concentration of the test 
compound,   
C: inhibitory activity (%) at the concentration B,  
D: inhibitory activity (%) at the concentration A.  
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 Figure 1. Structure of PD 404182. 
 
 
Figure 2. Strategy for the structural optimization of the PD 404182 derivatives 
 
 
Figure 3. Time-of-drug addition profiles for infection by a HIV-1IIIB strain of 
HeLa-CD4/CCR5-LTR/β-gal cells. 
 Scheme 1. Synthesis of 9-aryl-pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives. Reagents and 
conditions: (a) R-B(OH)2 or R-Bpin, Pd(PPh3)4, PdCl2(dppf)·CH2Cl2, K2CO3, toluene or 
1,4-dioxane, EtOH, H2O, reflux, 29%-quant.; (b) pyrazole or imidazole, CuCl, K2CO3, 




Scheme 2. Synthesis of spiropyrimidine-fused benzothiazinimine derivatives. Reagents and 
conditions: (a) (i) 4-methoxybenzoyl chloride, Et3N, CH2Cl2, rt; (ii) LiAlH4, Et2O, rt, 75% (2 steps); 
(b) malononitrile, DBU, DMF, 50°C, 8-60% (for 13 and 14); (c) malononitrile, K2CO3, DMF, 65°C, 
85% (for 15); (d) BH3, THF, 0°C to rt; (e) 4-bromo-2-fluorobenzaldehyde, I2, K2CO3, t-BuOH, 
70°C, 11-62% [2 steps (d,e)]; (f) NaH, t-BuNCS DMF, rt–80°C, 78-94%; (g) TFA, MS4Å, CHCl3, 
reflux, 66-72%. 
  
Scheme 3. Synthesis of derivatives 24b-e from 23a. Reagents and conditions: (a) ClCO2Me or 
AcCl, CH2Cl2, 0°C, 81-96% (for 23b or 23c); (b) (i) 1-chloroethyl chloroformate, Et3N, CH2Cl2, 
0°C, then MeOH, reflux, (ii) MsCl or TMSNCO, (Et3N), CH2Cl2, rt, 29-82% (2 steps, for 23d or 
23e); (c) TFA, MS4Å, CHCl3, reflux, 65-94%.
Table 1. Structure–activity relationships for biphenyl-type derivatives. 
 
a
 EC50 values represent the concentration of compound required to inhibit the HIV-1 infection by 
50% and were obtained from three independent experiments. 
Table 2. Structure–activity relationships for biaryl-type derivatives. 
 
a
 EC50 values represent the concentration of compound required to inhibit the HIV-1 infection by 
50% and were obtained from three independent experiments. 
b
 Cytotoxicity was observed at 10 M. 
Table 3. Structure–activity relationships for spiropyrimidine-fused derivatives. 
 
a
 EC50 values represent the concentration of compound required to inhibit the HIV-1 infection by 
50% and were obtained from three independent experiments.  
 








HIV-1NL4-3 0.38 ± 0.06 0.23 ± 0.09 
HIV-1BaL 0.37 ± 0.06 0.13 ± 0.05 
HIV-2EHO 0.31 ±0.06 0.14 ± 0.02 
HIV-2ROD 0.30 ± 0.06 0.10 ± 0.04 
a
 EC50 values represent the concentration of compound required to inhibit the HIV infection by 50% 
and were obtained from three independent experiments. 
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